1. Sanofi Reports Results for Sarclisa (Isatuximab) in P-III Trial for the Treatment of Newly Diagnosed Multiple Myeloma Patients

    By PharmaShots Shots: The P-III (IMROZ) clinical trial evaluates Sarclisa (10mg/kg, IV, qw) + VRd SoC (bortezomib, lenalidomide & dexamethasone) vs VRd alone in patients (n=484) with transplant-ineligible MM across 104 centers in 21 countries The 1EP of the study includes PFS & th